EsoBiotec
Belgium
acquiredacquired
acquired
Stage
2018
Founded
1
Investors
About
EsoBiotec develops cancer immunotherapies by engineering immune cells within the patient's body, aiming to improve cancer treatment through its proprietary ENaBL vector platform, which addresses costs and logistics of traditional cell therapies.
Explore EsoBiotec's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.